Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02XJY
|
|||
| Former ID |
DAP000229
|
|||
| Drug Name |
Midodrine
|
|||
| Synonyms |
Alphamine; Amatine; Gutron; Hipertan; Metligene; Midamine; Midodrin; Midodrina; Midodrinum; ProAmatine; MIDODRINE HYDROCHLORIDE; Midodrine HCL; Midodrine Monohydrochloride; Midodrine hydrochloride [USAN]; A 4020 Linz; St 1085; TS 701; A-4020 Linz; Midodrina [INN-Spanish]; Midodrine (INN); Midodrine [BAN:INN]; Midodrine [INN:BAN]; Midodrine hydrochloride [USAN:JAN]; Midodrinum [INN-Latin]; Pro-Amatine; Proamatine (TN); ST-1085; St. Peter 224; Midodrine hydrochloride (JAN/USAN); Pro-Amatine (TN); DL-N1-(beta-Hydroxy-2,5-dimethoxyphenethyl)glycinamid; N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]glycinamide; N-{2-[2,5-bis(methyloxy)phenyl]-2-hydroxyethyl}glycinamide; [+/-]-1-[2,5-Dimethoxyphenyl]-2-glycinamidoethanol; Acetamide, 2-amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)-, hydrochloride; Acetamide, 2-amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)-, monohydrochloride; (+-)-1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride; (+-)-2-Amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide monohydrochloride; (+-)-Midodrine hydrochloride; (+/-)-1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol; (-)-Midodrin hydrochloride; (-)-Midodrine hydrochloride; (RS)-N'-(beta-Hydroxy-2,5-dimethoxy-phenethyl)glycinamid; 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol; 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride; 1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamid; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamide; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethylacetamide; 2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)acetamide monohydrochloride; 2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hyyroxyethyl)acetamide monohydrochloride; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide hydrochloride
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Orthostatic hypotension [ICD-11: BA21; ICD-10: I95.1; ICD-9: 458] | Approved | [1], [2] | |
| Therapeutic Class |
Vasoconstrictor Agents
|
|||
| Company |
Shire Canada Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C12H18N2O4
|
|||
| Canonical SMILES |
COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O
|
|||
| InChI |
1S/C12H18N2O4/c1-17-8-3-4-11(18-2)9(5-8)10(15)7-14-12(16)6-13/h3-5,10,15H,6-7,13H2,1-2H3,(H,14,16)
|
|||
| InChIKey |
PTKSEFOSCHHMPD-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 42794-76-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10092, 7433691, 8152622, 11336130, 11361369, 11364535, 11367097, 11369659, 11372749, 11373902, 11377821, 11462341, 11466219, 11467339, 11485126, 11485798, 11489361, 11491400, 11492007, 11495455, 14847816, 29223300, 46507373, 47365278, 47365279, 47662374, 47736573, 47810835, 48035214, 48259327, 48416280, 49698958, 50064787, 50122851, 50122852, 50949507, 56464179, 57322186, 85788446, 96024908, 104305704, 124963568, 125684389, 128965708, 134222029, 134337543, 135002277, 137240087, 137248546, 142173049
|
|||
| ChEBI ID |
CHEBI:6933
|
|||
| ADReCS Drug ID | BADD_D01461 ; BADD_D01462 | |||
| SuperDrug ATC ID |
C01CA17
|
|||
| SuperDrug CAS ID |
cas=042794763
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor Alpha-1 (ADRA1) | Target Info | Agonist | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7240). | |||
| REF 2 | Emerging drugs for complications of end-stage liver disease. Expert Opin Emerg Drugs. 2008 Mar;13(1):159-74. | |||
| REF 3 | Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging. 2001;18(7):495-505. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.